SCIENCE-DRIVEN,

HUMAN-CENTERED

Harnessing the power of interleukin-10,
master anti-inflammatory cytokine

ribbon-3.jpg

OUR UNIQUE APPROACH

200 million worldwide suffer from chronic inflammatory diseases. There is a large unmet need for treatments for chronic inflammatory disease that are efficacious and safe. Xalud Therapeutics is developing a non-viral gene therapy targeting immune modulation. Our mission is to harness the power of interleukin-10 (IL-10), a potent anti-inflammatory cytokine, to address the root cause of inflammation and subsequently restore homeostasis in the immune system.

 
blue-male-front1.jpg

AN UPSTREAM TREATMENT FOR
CHRONIC INFLAMMATION THAT
RESTORES THE BODY’S BALANCE

 

OUR SCIENCE

A healthy, strong body lives in a state of equilibrium. Every day, it detects signals of injury or chronic disease progression and naturally restores itself by modulating anti-inflammatory cytokines and pro-inflammatory mediators. When the body is unbalanced, unfortunately, inflammation can flare and persist over long periods of time. This results in a myriad of diseases and associated symptoms like debilitating pain that prevents millions from living healthy productive lives.

Xalud Therapeutics aims to break this cycle of chronic, pathologic inflammation. Instead of masking, we help the body to restore the natural balance of inflammatory and restorative pathways by adding back one of its own defenses to increase anti-inflammatory signals.

OUR PLATFORM

IL-10 is a potent anti-inflammatory cytokine that inhibits and counterbalances effects of inflammatory cytokines. Insufficient IL-10 expression or signaling have been implicated in inflammation and numerous immune disease states. Our breakthrough therapeutic candidate, XT-150, addresses pathologic inflammation by expressing IL-10 locally to the sites of inflammation. Xalud is currently evaluating XT- 150 across multiple indications in preclinical and clinical studies. 

white-spine2.jpg
 
blue-male-back1.jpg

OUR PIPELINE

 

MUSCULOSKELETAL


Osteoarthritis

 

Degenerative Disc Disease

 

Facet Syndrome

 

CNS

 

Neuropathic Pain

 

Lumbar/Cervical Radiculitis

 

Multiple Sclerosis


OTHER TARGETS


Ophthalmic, Gastrointestinal, Dermal

PRE-CLINICAL    IND-ENABLING   PHASE 1/2    PHASE 2/3

blue-hand.jpg

OUR LEADERSHIP

 

DIEM NGUYEN, PHD, MBA

Chief Executive Officer

Bio

STEVE COLLINS, MD/PHD

Chief Medical Officer

Bio

KRISTEN ALBRIGHT

Commercial Development

Bio

MIKE HUSTON

Clinical Operations

Bio

RAYMOND CHAVEZ, PHD

R&D

Bio

PAUL MANNING

Chairman and CEO  |  PBM Capital

SEAN STALFORT

President  |  PBM Capital

JAYSON RIEGER, PHD, MBA

Operations  |  PBM Capital

SUNG YOU

Investor Relations  |  PBM Capital

JOE PEDERSEN

Manufacturing  |  PBM Capital

ADVISORS

John Forsayeth, PhD     Linda Watkins, PhD     Tarek Samad, PhD

Lee Simon, MD, FACP FACR      Nathaniel Katz, MD      Eric Grigsby, MD      Leonardo Kapura, MD

JOIN XALUD

At Xalud, we seek to address the significant unmet need for safe and efficient treatments for chronic pain-related diseases. Join us.

white-logo.png

40 West 57th Street, Suite 1810 New York, NY 10019  |  hello@xaludthera.com

© 2021 XALUD THERAPEUTICS